Medical Devices & ConsumablesTop Companies
Medical Devices & Consumables

Top Airway Stent/Lung Stent Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Medical Devices & Consumables

Published

Jan 2026

Share:

Medical Devices & Consumables

Top Airway Stent/Lung Stent Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size
0.41 Billion
2026 Forecast
0.43 Billion
2032 Forecast
0.60 Billion
CAGR (2026-2032)
5.90%

Summary

The Airway Stent/Lung Stent market is in a steady expansion phase, supported by rising COPD, lung cancer, and post‑COVID airway complications. Leading Airway Stent/Lung Stent market companies are consolidating share through innovation in flexible, drug‑eluting designs and minimally invasive delivery systems. From US$ 0.41 Billion in 2025, the market is forecast to reach US$ 0.60 Billion by 2032, reflecting a 5.90% CAGR.

2025 Revenue of Top Airway Stent/Lung Stent Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Airway Stent/Lung Stent market companies are derived from a composite scoring model that blends quantitative and qualitative indicators. Core metrics include estimated 2025 Airway Stent/Lung Stent revenue, multi‑year growth trajectory, and share within the global market valued at US$ 0.41 Billion. We also assess procedure volumes supported, installed base across key hospitals, and geographic diversification. Technology differentiation is weighted heavily, capturing innovation in stent materials, drug‑elution, imaging‑guided placement, and customization for benign versus malignant airway disease. Portfolio breadth, depth of bronchoscopic and thoracic surgery solutions, and service coverage in high‑acuity centers form additional pillars. Strategic factors—such as clinical trial pipeline, regulatory approvals, KOL partnerships, and ability to deliver training and long‑term maintenance contracts—are incorporated. Each company receives scores across all dimensions, normalized to generate a final ranking that reflects both current scale and future competitive positioning.

Top 10 Companies in Airway Stent/Lung Stent

1
Boston Scientific Corporation
Ultraflex Airway Stent System, Aero-style metal stents portfolio
Marlborough, MA, USA
Broad minimally invasive portfolio, strong physician loyalty, extensive KOL network in interventional pulmonology
Airway stents, interventional pulmonology, interventional cardiology, endoscopy
≈ 19.50%
Strong positions in North America, Western Europe, and growing presence in high‑tier Asian hospitals
Expanded clinical education programs in North America and Europe; incremental investments in next-generation fully covered airway stents.
US$ 0.08 Billion
2
Merit Medical Systems, Inc.
Aeris Tracheobronchial Stent, Merit Endotek airway solutions
South Jordan, UT, USA
Strong Endotek legacy, value‑oriented offerings, responsive OEM and private‑label capabilities
Interventional pulmonology, radiology, cardiology, specialty surgical devices
≈ 14.60%
North America core; expanding in Latin America, Middle East, and selective Asia Pacific markets
Broadened distribution in Latin America and EMEA; invested in R&D for improved stent deliverability and repositioning.
US$ 0.06 Billion
3
Taewoong Medical Co., Ltd.
Niti‑S Tracheobronchial Stent, customized nitinol stent series
Gyeonggi‑do, South Korea
Deep expertise in nitinol technology, flexible customization, competitive pricing
Gastrointestinal stents, airway stents, urology, interventional devices
≈ 12.20%
Strong Asia Pacific footprint; solid penetration in Europe via distributors
Accelerated OEM partnerships in Europe; expanded custom stent manufacturing capacity in Korea.
US$ 0.05 Billion
4
Micro-Tech (Nanjing) Co., Ltd.
MT Aero Airway Stents, Micro-Tech tracheobronchial series
Nanjing, China
Cost-competitive manufacturing, broad endoscopy ecosystem, strong domestic hospital relationships
Endoscopy accessories, GI stents, airway stents, single-use devices
≈ 9.80%
Dominant in China; rapidly expanding presence in Europe and Middle East
Scaled exports to Europe and LatAm; built new training centers with leading Chinese teaching hospitals.
US$ 0.04 Billion
5
Novatech SA (a Horus Group company)
Dumon Silicone Stent, Novatech Y‑Stent
La Ciotat, France
Gold standard in silicone stents, strong brand recognition among thoracic surgeons
Silicone airway stents, ENT devices, thoracic surgery solutions
≈ 7.30%
Strong in Western Europe; niche presence in North America and Latin America
Refreshed silicone portfolio with improved radiopacity; expanded direct sales presence in key EU markets.
US$ 0.03 Billion
6
Olympus Corporation
Olympus Airway Stent portfolio, bronchoscopic delivery systems
Tokyo, Japan
End‑to‑end visualization and therapy ecosystem, entrenched relationships with endoscopy suites
Endoscopes, therapeutic endoscopy, surgical devices, imaging
≈ 7.10%
Strong global footprint with particular depth in Japan, Europe, and North America
Integrated stent solutions with advanced bronchoscopes; leveraged bundled deals with large health systems.
US$ 0.03 Billion
7
Henan Tuoren Medical Device Co., Ltd.
Tuoren Airway Stent Series, Tuoren bronchoscopy disposables
Henan, China
High‑volume manufacturing, aggressive pricing, bundling with anesthesia and ICU consumables
Disposable medical supplies, anesthesia, critical care, stents
≈ 4.90%
Broad China coverage; growing export channels in Asia Pacific and Africa
Extended product registrations in Southeast Asia; invested in high‑volume automated stent production lines.
US$ 0.02 Billion
8
ELLA-CS, s.r.o.
Ella Airway Stents, self‑expanding nitinol stent line
Hradec Králové, Czech Republic
Flexibility in small‑batch customization, engineering collaboration with specialist centers
Gastrointestinal and airway stents, custom implants
≈ 4.40%
Strong Central/Eastern European presence; selective exports to Western Europe and Middle East
Focused on niche custom solutions; secured new distributors in Central and Eastern Europe.
US$ 0.02 Billion
9
Cook Medical LLC
PolyFlex Airway Stent, Cook tracheobronchial devices
Bloomington, IN, USA
Reputation for complex-case solutions, strong regulatory and clinical evidence base
Interventional radiology, vascular, endoscopy, pulmonology
≈ 3.80%
North America and Europe with long‑standing hospital relationships
Rationalized product portfolio; focused on high‑value niche airway indications and complex cases.
US$ 0.01 Billion
10
Boston Medical Products, Inc.
Montgomery T‑Tubes, Boston Medical tracheal stents
Westborough, MA, USA
Highly specialized ENT focus, strong brand in airway reconstruction implants
ENT, airway reconstruction, tracheal and laryngeal implants
≈ 2.40%
Niche presence in North American and European tertiary care centers
Expanded surgeon education for airway reconstruction; targeted pediatric and complex airway centers globally.
US$ 0.01 Billion

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Boston Scientific Corporation

Boston Scientific is a global medtech leader with a diversified minimally invasive portfolio, including advanced airway stent systems and interventional pulmonology solutions.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.08 Billion; estimated segment growth 6.10% CAGR 2025-2032.
Flagship Products: Ultraflex Airway Stent System, Aero-style metallic stents, bronchoscopic delivery catheters
2025-2026 Actions: Scaled clinical training, reinforced KOL collaborations, and invested in next-generation fully covered and drug-eluting airway stent platforms.
Three-line SWOT: Extensive global sales and service network; Premium pricing versus Asian competitors; Opportunity—rising complex airway procedures in emerging markets.
Notable Customers: Cleveland Clinic, Mayo Clinic, Charité – Universitätsmedizin Berlin
2

Merit Medical Systems, Inc.

Merit Medical offers a broad Endotek-branded portfolio spanning interventional pulmonology, gastroenterology, and radiology, emphasizing value and procedural efficiency.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.06 Billion; operating margin in endoscopy-related lines estimated at 15.20%.
Flagship Products: Aeris Tracheobronchial Stent, Merit Endotek airway stents, Merit airway delivery systems
2025-2026 Actions: Expanded EMEA and Latin American distribution, optimized stent deliverability, and launched new education programs for bronchoscopists.
Three-line SWOT: Strong Endotek brand and channel reach; Relatively smaller R&D budget than top-tier giants; Opportunity—mid-tier hospitals seeking cost-effective solutions.
Notable Customers: HCA Healthcare, Hospital Sírio-Libanês, leading regional community hospitals
3

Taewoong Medical Co., Ltd.

Taewoong Medical specializes in nitinol-based stents for gastrointestinal and airway applications, with strong customization capabilities and a global OEM footprint.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.05 Billion; export-driven revenue share above 70.00%.
Flagship Products: Niti-S Tracheobronchial Stent, Niti-S Y-shaped airway stent, customized nitinol airway implants
2025-2026 Actions: Expanded OEM relationships in Europe, strengthened regulatory approvals, and increased production capacity for custom airway stents.
Three-line SWOT: Deep nitinol engineering expertise; Limited direct-brand recognition in some Western markets; Opportunity—customized stents for complex benign airway disease.
Notable Customers: University Hospital Frankfurt, major Korean tertiary centers, OEM partners in Europe
4

Micro-Tech (Nanjing) Co., Ltd.

Micro-Tech is a fast-growing Chinese manufacturer of endoscopy accessories and stents, increasingly active in export markets across Europe and Latin America.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.04 Billion; R&D spending approximately 8.50% of total revenue.
Flagship Products: MT Aero Airway Stents, Micro-Tech tracheobronchial metal stents, bronchoscopic accessories
2025-2026 Actions: Scaled international sales teams, built regional training hubs, and broadened airway stent regulatory approvals in Europe.
Three-line SWOT: Cost-competitive manufacturing base; Perception gap on quality in some premium markets; Opportunity—value procurement in public health systems.
Notable Customers: Large Chinese teaching hospitals, public hospitals in Brazil, regional distributors in Europe
5

Novatech SA (a Horus Group company)

Novatech is a pioneer in silicone airway stents, widely recognized for its Dumon range used in benign and malignant airway stenosis.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.03 Billion; silicone stent line accounting for over 80.00% of segment sales.
Flagship Products: Dumon Silicone Stent, Novatech Y-Stent, related airway instruments
2025-2026 Actions: Optimized silicone formulations, invested in radiopaque markers, and enhanced presence in key European thoracic centers.
Three-line SWOT: Iconic Dumon brand with strong clinical heritage; Limited metal stent offering; Opportunity—growing demand for removable silicone stents.
Notable Customers: Gustave Roussy, Royal Brompton Hospital, specialized thoracic surgery centers
6

Olympus Corporation

Olympus leads in endoscopic visualization and provides integrated therapeutic solutions, including airway stents paired with advanced bronchoscopic platforms.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.03 Billion; strong cross-selling uplift from installed bronchoscope base.
Flagship Products: Olympus Airway Stent range, bronchoscopic placement kits, therapeutic bronchoscopes
2025-2026 Actions: Bundled airway stents with endoscopy contracts, reinforced training on combined imaging and stenting procedures worldwide.
Three-line SWOT: Extensive installed imaging base; Airway stents are not a core revenue driver; Opportunity—leveraging integrated system deals with large hospital networks.
Notable Customers: Japanese national university hospitals, NHS trusts, U.S. integrated delivery networks
7

Henan Tuoren Medical Device Co., Ltd.

Henan Tuoren is a large Chinese supplier of disposable devices and critical care products, increasingly adding interventional airway stents to its portfolio.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.02 Billion; double-digit growth in export sales above 12.40%.
Flagship Products: Tuoren Airway Stent Series, bronchoscopy disposables, anesthesia breathing circuits
2025-2026 Actions: Expanded registrations across ASEAN, automated stent production, and used consumables bundling to penetrate new hospitals.
Three-line SWOT: Scale and low-cost production; Limited premium-brand perception in developed markets; Opportunity—tier-2 and tier-3 hospital expansion in Asia and Africa.
Notable Customers: Chinese provincial hospitals, Southeast Asian public hospitals, private hospital chains in emerging markets
8

ELLA-CS, s.r.o.

ELLA-CS is a European specialist in self-expanding stents with strong customization services for complex gastrointestinal and airway indications.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.02 Billion; custom solutions representing roughly 35.00% of airway stent sales.
Flagship Products: Ella Airway Stents, custom nitinol tracheobronchial stents, GI stent portfolio
2025-2026 Actions: Broadened custom design collaborations with university hospitals and upgraded manufacturing for quick-turn small-batch production.
Three-line SWOT: High customization and engineering support; Smaller scale than global majors; Opportunity—growing demand for patient-specific implants.
Notable Customers: Motol University Hospital, regional European thoracic centers, specialist clinics in the Middle East
9

Cook Medical LLC

Cook Medical provides a wide portfolio of interventional products, including niche airway stents favored in complex and rare indications.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.01 Billion; focus on higher-margin specialty indications.
Flagship Products: PolyFlex Airway Stent, tracheobronchial accessories, interventional pulmonology tools
2025-2026 Actions: Refined product mix, emphasized complex-case support services, and deepened relationships with leading thoracic programs.
Three-line SWOT: Strong clinical reputation in complex cases; Limited breadth of airway portfolio; Opportunity—leveraging expertise for referral-center partnerships.
Notable Customers: Massachusetts General Hospital, University of Toronto-affiliated centers, select European reference hospitals
10

Boston Medical Products, Inc.

Boston Medical Products focuses on ENT and airway reconstruction devices, with specialized solutions for laryngeal and tracheal disorders.

Key Financials: 2025 Airway Stent/Lung Stent revenue US$ 0.01 Billion; niche ENT implants achieving stable mid-single-digit growth.
Flagship Products: Montgomery T-Tubes, tracheal stents, laryngeal implants
2025-2026 Actions: Expanded global surgeon training, targeted pediatric airway centers, and refined product line for reconstructive procedures.
Three-line SWOT: Strong brand in ENT reconstruction; Narrow product scope and scale; Opportunity—rising volume of complex reconstructive airway surgeries.
Notable Customers: Children’s Hospital of Philadelphia, Great Ormond Street Hospital, specialized ENT surgery centers

SWOT Leaders

Boston Scientific Corporation

SWOT Snapshot

SWOT
Strengths

Global distribution network, diversified interventional portfolio, strong clinical evidence and deep KOL engagement in interventional pulmonology.

Weaknesses

Premium pricing, complex organizational structure, and dependence on bundled capital-equipment relationships in some markets.

Opportunities

Expanding complex airway procedures, aging populations, and rising lung cancer incidence in emerging economies.

Threats

Price pressure from Asian manufacturers, reimbursement constraints, and potential regulatory tightening on implantable devices.

Merit Medical Systems, Inc.

SWOT Snapshot

SWOT
Strengths

Focused Endotek brand, agile decision-making, competitive pricing and strong relationships with interventional pulmonologists.

Weaknesses

Smaller R&D budget versus largest medtech players and lower brand visibility outside core markets.

Opportunities

Penetration of mid-tier hospitals, new indication-driven product variants, and geographic expansion in Latin America and EMEA.

Threats

Intensifying competition from both global majors and aggressive regional players, as well as supply chain cost volatility.

Taewoong Medical Co., Ltd.

SWOT Snapshot

SWOT
Strengths

Advanced nitinol engineering, strong customization capability, and robust OEM partnerships across Europe and Asia.

Weaknesses

Limited direct-branded sales presence in North America and relatively modest marketing resources.

Opportunities

Growing demand for patient-specific stents and increasing recognition of Asia-based quality manufacturers globally.

Threats

Dependence on distributor networks, currency fluctuations, and pressure from low-cost Chinese competitors.

Airway Stent/Lung Stent Market Regional Competitive Landscape

North America remains the largest revenue contributor, driven by high COPD and lung cancer prevalence, advanced bronchoscopic infrastructure, and favorable reimbursement. Boston Scientific Corporation, Merit Medical Systems, and Cook Medical anchor the competitive landscape, while specialized ENT solutions from Boston Medical Products serve high-complexity reconstructive centers.

Europe shows strong demand for both silicone and metal airway stents, with Western Europe emphasizing evidence-backed, premium solutions. Novatech’s Dumon silicone stents enjoy iconic status, while Boston Scientific, Taewoong Medical, and Olympus compete in interventional pulmonology suites. Central and Eastern Europe rely more heavily on ELLA-CS and Micro-Tech for cost-effective options.

Asia Pacific is the fastest-growing region, supported by rapid healthcare infrastructure expansion, rising procedure volumes, and improving bronchoscopy access. Taewoong Medical and Micro-Tech lead among regional players, while Olympus leverages its dominant endoscope base. Henan Tuoren’s aggressive pricing allows penetration into tier-2 hospitals, challenging established Airway Stent/Lung Stent market companies.

Latin America remains comparatively underpenetrated but offers meaningful upside as tertiary centers expand interventional pulmonology capabilities. Merit Medical Systems and Micro-Tech are increasingly visible through regional distributors. Public procurement often favors competitively priced offerings, providing opportunities for cost-focused Airway Stent/Lung Stent market companies to scale share.

The Middle East and Africa region is characterized by pockets of high-end demand in Gulf Cooperation Council countries, contrasted with limited access elsewhere. Boston Scientific and Olympus focus on reference centers, while Chinese manufacturers such as Henan Tuoren and Micro-Tech capture government tenders. Training and service support are critical differentiators for Airway Stent/Lung Stent market companies in these geographies.

Airway Stent/Lung Stent Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

AirwayX BioDesign
Disruptor
USA

Developing 3D-printed, patient-specific silicone airway stents with rapid design-to-implant workflows integrated into hospital imaging systems.

Stentigen MedTech
Disruptor
Germany

Pursuing bioresorbable airway stent platforms that aim to eliminate removal procedures and reduce long-term foreign-body complications.

BronchoSmart Solutions
Disruptor
India

Offers AI-guided planning software for airway stent sizing and placement, interoperable with leading bronchoscopes and CT imaging suites.

NeoLung Therapeutics
Disruptor
Belgium

Combines drug-eluting coatings with metal airway stents to target local anti-inflammatory and anti-proliferative delivery in complex stenosis.

APAC StentWorks
Disruptor
Singapore

Regional OEM focused on cost-efficient nitinol stents, aiming to support private hospital chains across Southeast Asia and Middle East.

Airway Stent/Lung Stent Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Airway Stent/Lung Stent market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Airway Stent/Lung Stentmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.